Repligen Corporation (RGEN)
- Previous Close
150.75 - Open
151.12 - Bid 150.56 x 200
- Ask 151.12 x 200
- Day's Range
148.85 - 152.33 - 52 Week Range
110.45 - 211.13 - Volume
3,728,546 - Avg. Volume
898,477 - Market Cap (intraday)
8.453B - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-0.03 - Earnings Date Oct 29, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
192.07
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
www.repligen.com1,783
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: RGEN
View MorePerformance Overview: RGEN
Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGEN
View MoreValuation Measures
Market Cap
8.45B
Enterprise Value
8.38B
Trailing P/E
466.37
Forward P/E
105.26
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.06
Price/Book (mrq)
4.25
Enterprise Value/Revenue
13.91
Enterprise Value/EBITDA
91.14
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.32%
Return on Assets (ttm)
0.19%
Return on Equity (ttm)
-0.10%
Revenue (ttm)
602.35M
Net Income Avi to Common (ttm)
-1.9M
Diluted EPS (ttm)
-0.03
Balance Sheet and Cash Flow
Total Cash (mrq)
809.15M
Total Debt/Equity (mrq)
37.40%
Levered Free Cash Flow (ttm)
120.45M